


Annexure 1: IIPS-IRB Application form

INTERNATIONAL INSTITUTE FOR POPULATION SCIENCES	
 <p>Deemed-to-Be-University B. S. Devashi Marg (Govandi Station Road) Deonar, Mumbai, Maharashtra 400088, https://www.iipsindia.ac.in/</p>	<p style="text-align: center;">IIPS-IRB Application form</p> <p>Serial No of IIPS-IRB Management Office: _____</p>

International Institute for Population Sciences -Institutional Review Board (IIPS-IRB) Application form for the review of the proposal

General instructions:

- a) To be filled by the Principal Investigator (PI);
- b) Please tick mark the appropriate one, mark NA if not applicable; and
- c) Attach a separate sheet if required

Title of the Proposal:

.....
.....

Name of the Applicant

Name of the Principal Investigator

Designation:

.....
.....

Department:

.....
.....

Date of submission

Type of review

Exemption from Review ... ☐ Expedited Review . ☐ Full Committee Review .. ☐

Status of Review: New ☐ Revised ☐

SECTION A: ADMINISTRATIVE INFORMATION				
Project Investigators	Name, Qualifications and Designation	Department and Organization Address and contact details	Roles and responsibilities	Signature
PI:				

SECTION A: ADMINISTRATIVE INFORMATION				
Project Investigators	Name, Qualifications and Designation	Department and Organization Address and contact details	Roles and responsibilities	Signature
Co-PI:				

Please attach a brief bio and CV for all investigators (PIs and Co-PIs) involved in the study (with subject specific publications limited to the previous 5 years).

Funding Details

Project Duration:
Total Budget:
Share of the sponsor/s in total budget
Sponsor Information: 1. Indian a) Government <input type="checkbox"/> i. Central <input type="checkbox"/> ii. State <input type="checkbox"/> iii. Institutional <input type="checkbox"/> b) Private <input type="checkbox"/> i. Industry <input type="checkbox"/> ii. Development agency <input type="checkbox"/> iii. Self-sponsored <input type="checkbox"/> 2. International Government <input type="checkbox"/> Private <input type="checkbox"/> UN agencies <input type="checkbox"/> Other <input type="checkbox"/> 3. Industry National <input type="checkbox"/> Multinational <input type="checkbox"/>
Specify the funding agency
Contact Address of Sponsor:

SECTION B: RESEARCH RELATED INFORMATION
1. Brief description of the study –background, research question aim(s) & objectives, methodology describing the potential risks & benefits, monitoring and auditing, outcome measures, statistical analysis and implication of the research findings (maximum 500 words):
2. Objectives of the study
1. Type of Study:

Socio-Behavioural Science <input type="checkbox"/>	Retrospective <input type="checkbox"/>	Cross sectional <input type="checkbox"/>
Clinical Single center <input type="checkbox"/>	Prospective <input type="checkbox"/>	Longitudinal/cohort <input type="checkbox"/>
Clinical Multi- centeric <input type="checkbox"/>	Quantitative <input type="checkbox"/>	Case control <input type="checkbox"/>
Epidemiological and Public health <input type="checkbox"/>	Qualitative <input type="checkbox"/>	Systematic review <input type="checkbox"/>
Basic science <input type="checkbox"/>	Mixed method <input type="checkbox"/>	Baseline <input type="checkbox"/>
Biological sample <input type="checkbox"/>		Endline <input type="checkbox"/>
		Formative <input type="checkbox"/>

3. Clinical Trials:
Drug /Vaccines/Device/Herbal Remedies:

i. Does the study involve use of:

Drug <input type="checkbox"/>	Devices <input type="checkbox"/>	Vaccine <input type="checkbox"/>	<input type="checkbox"/>
Indian Systems of Medicine/ Alternate System of Medicine <input type="checkbox"/>	Any other <input type="checkbox"/>	NA <input type="checkbox"/>	<input type="checkbox"/>

ii. Is it approved and marketed

In India <input type="checkbox"/>	UK & Europe <input type="checkbox"/>	USA <input type="checkbox"/>
Other countries, specify <input type="checkbox"/>		

iii. Does it involve a change in use, dosage, route of administration?	Yes	No
If yes, whether DCGI's /Any other Regulatory authority's Permission is obtained?	Yes	No
If yes, Date of permission :		
iv. Is it an Investigational New Drug?	Yes	No
If yes, IND No:		
a). Investigator's Brochure submitted	Yes	No
b). <i>In vitro</i> studies data	Yes	No
c). Preclinical Studies done	Yes	No
d). Clinical Study is : Phase I <input type="checkbox"/> Phase II <input type="checkbox"/> Phase III <input type="checkbox"/> Phase IV <input type="checkbox"/>		

4. Are you aware if this study/similar study is being done elsewhere?

Yes	No
If Yes, provide details	

SECTION C: PARTICIPANT RELATED INFORMATION

5. Subject selection:

i. Number of Subjects: Sampling design and Sample Size

The rationale for the selection of sample size in 100 words. In case of qualitative study describe the number and type of respondents.			
ii. Duration of fieldwork :			
iii. Will subjects from both sexes be recruited			Yes <input type="checkbox"/> No <input type="checkbox"/>
iv. Please provide the inclusion and exclusion criteria of the selection of respondents			
v. Type of subjects Volunteers <input type="checkbox"/> Patients <input type="checkbox"/>			
vi. Vulnerable subjects			Yes <input type="checkbox"/> No <input type="checkbox"/>
If Vulnerable subjects, Tick the appropriate boxes			
Pregnant Women <input type="checkbox"/> Children <input type="checkbox"/> Elderly <input type="checkbox"/> Fetus <input type="checkbox"/> Illiterate <input type="checkbox"/> Handicapped <input type="checkbox"/> Terminally ill <input type="checkbox"/> Seriously ill <input type="checkbox"/> Mentally challenged <input type="checkbox"/> economically & socially backward <input type="checkbox"/> Any other (Specify) <input type="checkbox"/>			
iv. Special group subjects			Yes <input type="checkbox"/> No <input type="checkbox"/>
If yes in special subject group, tick the appropriate boxes)			
Captives <input type="checkbox"/> Institutionalized <input type="checkbox"/> Employees <input type="checkbox"/> Students <input type="checkbox"/> Nurses/Dependent <input type="checkbox"/> Armed <input type="checkbox"/> Any Other <input type="checkbox"/> Staff <input type="checkbox"/> Forces <input type="checkbox"/>			
6. Privacy and confidentiality			
i. Study involves -		Direct Identifiers <input type="checkbox"/> Indirect Identifiers/coded <input type="checkbox"/> Completely anonymised/ delinked <input type="checkbox"/>	
ii. Confidential handling of data by staff		Yes <input type="checkbox"/>	No <input type="checkbox"/> NA <input type="checkbox"/>
7. Use of biological/ hazardous materials		Yes <input type="checkbox"/>	No <input type="checkbox"/> NA <input type="checkbox"/>
i. Use of fetal tissue or abortus		Yes <input type="checkbox"/>	No <input type="checkbox"/> NA <input type="checkbox"/>
ii. Use of organs or body fluids		Yes <input type="checkbox"/>	No <input type="checkbox"/> NA <input type="checkbox"/>
iii. Use of recombinant/gene therapy		Yes <input type="checkbox"/>	No <input type="checkbox"/> NA <input type="checkbox"/>

If yes, has Department of Biotechnology (DBT) approval for DNA products been obtained?	Yes	No	NA
iv. Use of pre-existing/stored/left over samples	Yes	No	NA
v. Collection for banking/future research	Yes	No	NA
vi. Use of ionising radiation/radioisotopes If yes, has Bhaba Atomic Research Centre (BARC) approval for Radioactive Isotopes been obtained?	Yes	No	NA
vii. Use of Infectious/biohazardous specimens	Yes	No	NA
viii. Proper disposal of material	Yes	No	NA
ix. Will any sample collected from the patients be sent abroad?	Yes	No	NA
If Yes, justify with details of collaborators:			
a) Is the proposal being submitted for clearance from Health Ministry's Screening Committee (HMSC) for International collaboration?		Yes	No
b) Sample will be sent abroad because (Tick appropriate box): <div style="display: flex; justify-content: space-between;"> <div> Facility not available in India Facility in India inaccessible Facility available but not being accessed. If so, reasons... </div> <div style="text-align: right;"> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> </div> </div>			
Informed Consent Are you seeking waiver of consent? If yes, please specify reasons and skip to item no. 8 Yes <input type="checkbox"/> No <input type="checkbox"/>			
Type of consent planned *Written/Signed <input type="checkbox"/> Oral/Verbal <input type="checkbox"/> Audio-visual <input type="checkbox"/>			
In case of a minor children <div style="display: flex; justify-content: space-between;"> <div>Verbal assent from o minor (7-12 yrs)along with parental consent</div> <div>Written assent from o minor (13-18 yrs) along with parental consent</div> </div>			
List of languages in which translation is done			
Details of number of consent or/assent to be obtained in the study			

<p>i.: Tick the included elements in the Consent form</p> <table style="width: 100%; border: none;"> <tr> <td style="width: 40%;">Understandable language</td> <td style="width: 10%; text-align: center;"><input type="checkbox"/></td> <td style="width: 40%;">Alternatives to participation</td> <td style="width: 10%; text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Statement that study involves research</td> <td style="text-align: center;"><input type="checkbox"/></td> <td>Confidentiality of records</td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Sponsor of study</td> <td style="text-align: center;"><input type="checkbox"/></td> <td>Contact information</td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Purpose and procedures</td> <td style="text-align: center;"><input type="checkbox"/></td> <td>Statement that consent is voluntary</td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Risks & Discomforts</td> <td style="text-align: center;"><input type="checkbox"/></td> <td>Right to withdraw</td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Benefits</td> <td style="text-align: center;"><input type="checkbox"/></td> <td>Consent for future use of biological material</td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Compensation for participation</td> <td style="text-align: center;"><input type="checkbox"/></td> <td>Benefits if any on future commercialization</td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Compensation for study related injury</td> <td style="text-align: center;"><input type="checkbox"/></td> <td>eg. genetic basis for drug development</td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Translated in local language</td> <td style="text-align: center;"><input type="checkbox"/></td> <td>Need to recontact</td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> </table> <p style="margin-top: 20px;">*If written consent is not obtained, give reasons:</p>				Understandable language	<input type="checkbox"/>	Alternatives to participation	<input type="checkbox"/>	Statement that study involves research	<input type="checkbox"/>	Confidentiality of records	<input type="checkbox"/>	Sponsor of study	<input type="checkbox"/>	Contact information	<input type="checkbox"/>	Purpose and procedures	<input type="checkbox"/>	Statement that consent is voluntary	<input type="checkbox"/>	Risks & Discomforts	<input type="checkbox"/>	Right to withdraw	<input type="checkbox"/>	Benefits	<input type="checkbox"/>	Consent for future use of biological material	<input type="checkbox"/>	Compensation for participation	<input type="checkbox"/>	Benefits if any on future commercialization	<input type="checkbox"/>	Compensation for study related injury	<input type="checkbox"/>	eg. genetic basis for drug development	<input type="checkbox"/>	Translated in local language	<input type="checkbox"/>	Need to recontact	<input type="checkbox"/>
Understandable language	<input type="checkbox"/>	Alternatives to participation	<input type="checkbox"/>																																				
Statement that study involves research	<input type="checkbox"/>	Confidentiality of records	<input type="checkbox"/>																																				
Sponsor of study	<input type="checkbox"/>	Contact information	<input type="checkbox"/>																																				
Purpose and procedures	<input type="checkbox"/>	Statement that consent is voluntary	<input type="checkbox"/>																																				
Risks & Discomforts	<input type="checkbox"/>	Right to withdraw	<input type="checkbox"/>																																				
Benefits	<input type="checkbox"/>	Consent for future use of biological material	<input type="checkbox"/>																																				
Compensation for participation	<input type="checkbox"/>	Benefits if any on future commercialization	<input type="checkbox"/>																																				
Compensation for study related injury	<input type="checkbox"/>	eg. genetic basis for drug development	<input type="checkbox"/>																																				
Translated in local language	<input type="checkbox"/>	Need to recontact	<input type="checkbox"/>																																				
<p>ii. Who will obtain consent ?</p> <table style="width: 100%; border: none;"> <tr> <td style="width: 30%;">PI/Co-PI</td> <td style="width: 10%; text-align: center;"><input type="checkbox"/></td> <td style="width: 30%;">Nurse/Counsellor</td> <td style="width: 10%; text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Research staff</td> <td style="text-align: center;"><input type="checkbox"/></td> <td>Any other</td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> </table>				PI/Co-PI	<input type="checkbox"/>	Nurse/Counsellor	<input type="checkbox"/>	Research staff	<input type="checkbox"/>	Any other	<input type="checkbox"/>																												
PI/Co-PI	<input type="checkbox"/>	Nurse/Counsellor	<input type="checkbox"/>																																				
Research staff	<input type="checkbox"/>	Any other	<input type="checkbox"/>																																				
<p>8. Payment/Compensation</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 80%; padding: 5px;">Will you provide any form of payment/compensation to the participants as a result of their participation?</td> <td style="width: 10%; text-align: center; padding: 5px;">Yes</td> <td style="width: 10%; text-align: center; padding: 5px;">No</td> </tr> <tr> <td style="padding: 5px;">Ye yes, please give details of the payment/compensation</td> <td style="height: 40px;"></td> <td style="height: 40px;"></td> </tr> </table>				Will you provide any form of payment/compensation to the participants as a result of their participation?	Yes	No	Ye yes, please give details of the payment/compensation																																
Will you provide any form of payment/compensation to the participants as a result of their participation?	Yes	No																																					
Ye yes, please give details of the payment/compensation																																							
<p>9. Will any advertising be done for recruitment of Subjects? (posters, flyers, brochure, websites – if so kindly attach a copy)</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 80%;"></td> <td style="width: 10%; text-align: center;">Yes</td> <td style="width: 10%; text-align: center;">No</td> </tr> </table>					Yes	No																																	
	Yes	No																																					
<p>10. Risks & Benefits:</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 80%; padding: 5px;"> <p>ii. Is there physical / social / psychological risk / discomfort?</p> <p>If Yes, Minimal or no risk <input type="checkbox"/></p> <p>More than minimum risk <input type="checkbox"/></p> <p>High risk <input type="checkbox"/></p> </td> <td style="width: 10%; text-align: center; padding: 5px;">Yes</td> <td style="width: 10%; text-align: center; padding: 5px;">No</td> </tr> </table>				<p>ii. Is there physical / social / psychological risk / discomfort?</p> <p>If Yes, Minimal or no risk <input type="checkbox"/></p> <p>More than minimum risk <input type="checkbox"/></p> <p>High risk <input type="checkbox"/></p>	Yes	No																																	
<p>ii. Is there physical / social / psychological risk / discomfort?</p> <p>If Yes, Minimal or no risk <input type="checkbox"/></p> <p>More than minimum risk <input type="checkbox"/></p> <p>High risk <input type="checkbox"/></p>	Yes	No																																					
<p>In case if risks are involved, mention the risks and risk addressing mechanism:</p> <p>Risk</p> <p>Risk addressal mechanism</p>																																							

ii. Is there a potential benefit ?			
a) to the subject	<input type="checkbox"/> No benefit	<input type="checkbox"/> Direct benefit	<input type="checkbox"/> Indirect benefit
b) to the society	<input type="checkbox"/> No benefit	<input type="checkbox"/> Direct benefit	<input type="checkbox"/> Indirect benefit
c) for improvement in knowledge	<input type="checkbox"/> No benefit	<input type="checkbox"/> Direct benefit	<input type="checkbox"/> Indirect benefit
Mention the benefits:			
Storage And Confidentiality			
a) Identifying Information: Study Involves samples/data. If Yes, Specify			
Yes <input type="checkbox"/> No <input type="checkbox"/> NA <input type="checkbox"/>			
Anonymous/unidentified <input type="checkbox"/> Anonymized: reversibly coded <input type="checkbox"/> Irreversibly coded <input type="checkbox"/>			
Identifiable <input type="checkbox"/>			
If identifiers must be retained, what additional precautions will be taken to ensure that access is limited / data is safeguarded? (e.g. data stored in a cabinet, password protected computer etc.)			
b) Who will be maintaining the data pertaining to the study?			
c) Where will the data be analyzed and by whom?			
d) For how long will the data be stored?			
e) Do you propose to use stored samples/data in future studies?			
Yes <input type="checkbox"/> No <input type="checkbox"/> Maybe <input type="checkbox"/>			
If yes, explain how you might use stored material/data in the future?			
SECTION D: OTHER ISSUES			
11. Data Monitoring			
i. Is there a data & safety monitoring committee/ Board (DSMB)?	Yes No		
ii. Is there a plan for reporting of adverse events?	Yes No		
If Yes , reporting is done to:			
Sponsor <input type="checkbox"/> Ethics Committee <input type="checkbox"/> DSMB <input type="checkbox"/>			
iii. Is there a plan for interim analysis of data?	Yes No		
vi. Are there plans for storage and maintenance of all trial database?	Yes No		
If Yes , for how long? <input type="checkbox"/> <input type="checkbox"/>			


12. Is there compensation for participation? If Yes, Monetary <input type="checkbox"/> In kind <input type="checkbox"/> Specify amount and type:	Yes	No
13. Is there compensation for injury? If Yes, by Sponsor <input type="checkbox"/> by Investigator <input type="checkbox"/> by insurance <input type="checkbox"/> by any other <input type="checkbox"/> company	Yes	No
14. Do you have conflict of interest? (financial/nonfinancial) If Yes, specify :	Yes	No
SECTION E: CHECK LIST AND DECLARATION		
Cover letter	Yes	No NA
Copy of filled-in and duly signed IRB Form (4 copies)	Yes	No NA
Project proposal – 4 Copies	Yes	No NA
Short bio of the invigilators	Yes	No NA
Curriculum Vitae of Investigators in prescribed format	Yes	No NA
In case of collaborative research, attach the MOU with the collaborating organization	Yes	No NA
Format of review type	Yes	No NA
Participant information sheet-cum-Informed Consent form, (if multiple respondents, consent should be taken from each respondent)	Yes	No NA
Informed Assent form (If applicable)	Yes	No NA
Investigator self-declaration form	Yes	No NA
Questionnaire and/or Copy of clinical trial protocol and/or interview guidelines	Yes	No NA
Investigator's brochure for recruiting subjects	Yes	No NA

Copy of advertisements/Information brochures	Yes	No	NA
Institutional Animal Ethics Committee clearance	Yes	No	NA
Any other specify	Yes	No	NA
CPCSEA clearance, if any	Yes	No	NA
HMSC/DCGI/DBT/BARC clearance if obtained	Yes	No	NA
Survey Protocol on COVID-related Measures	Yes	No	NA

Date:
Place:


Principal Investigator

Annexure 2: CV format for Investigators


INTERNATIONAL INSTITUTE FOR POPULATION SCIENCES	
 <p>Deemed-to-Be-University B. S. Devashi Marg (Govandi Station Road) Deonar, Mumbai, Maharashtra 400088, https://www.iipsindia.ac.in/</p>	<p>IIPS-IRB CV Format for Investigators</p>

Format Curriculum Vitae for Investigators

Name:	
Present affiliation (<i>Job title, department, and organisation</i>):	
Address (<i>Full work address</i>):	
Telephone number:	Email address:
Qualifications:	
Previous and other affiliations (<i>Include previous affiliations in the last 5 years</i>):	
Projects undertaken in the last five years:	
Relevant research training/experience in the area:	

Attended Ethical Training (if any):	
Relevant Publications (<i>Give references to all relevant publications in the last five years</i>):	
Signature 	Date: Click here to enter a date.

Annexure 3: Expedited Review

INTERNATIONAL INSTITUTE FOR POPULATION SCIENCES																			
 <p>Deemed-to-Be-University B. S. Devashi Marg (Govandi Station Road) Deonar, Mumbai, Maharashtra 400088, https://www.iipsindia.ac.in/</p>	<h3>IIPS-IRB Expedited Review Form</h3>																		
<p>Title of study:</p> <p>Principal Investigator (Name, Designation, and Affiliation):</p>																			
<p>1. Choose reasons why expedited review from EC is requested¹?</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tbody> <tr> <td style="padding: 5px;">i. Involve non-identifiable specimen and human tissue from sources like blood banks, tissue banks and left-over clinical samples</td> <td style="text-align: center; width: 50px;"><input type="checkbox"/></td> </tr> <tr> <td style="padding: 5px;">ii. Involve clinical documentation materials that are non-identifiable (data, documents, records).</td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td style="padding: 5px;">iii. Modification or amendment to approved protocol (administrative changes/correction of typographical errors and change in researcher(s))</td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td style="padding: 5px;">iv. Revised proposals previously approved through expedited review, full review or continuing review of approved proposals</td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td style="padding: 5px;">v. Minor deviations from originally approved research causing no risk or minimal risk</td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td style="padding: 5px;">vi. Progress/annual reports where there is no additional risk, for example activity limited to data analysis. Expedited review of SAEs/unexpected AEs will be conducted by SAE subcommittee.</td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td style="padding: 5px;">vii. For multicentre research where a designated EC has approved the proposal, a participating EC may review participating centre specific information and modification in the study proposal through full committee meeting/ expedited review depending on the importance of local consent related issues involved specific to the centre.</td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td style="padding: 5px;">viii. Research during emergencies and disasters (See Section 12 of ICMR Ethical Guidelines, 2017).</td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td style="padding: 5px;">ix. Any other (please specify)</td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> </tbody> </table>		i. Involve non-identifiable specimen and human tissue from sources like blood banks, tissue banks and left-over clinical samples	<input type="checkbox"/>	ii. Involve clinical documentation materials that are non-identifiable (data, documents, records).	<input type="checkbox"/>	iii. Modification or amendment to approved protocol (administrative changes/correction of typographical errors and change in researcher(s))	<input type="checkbox"/>	iv. Revised proposals previously approved through expedited review, full review or continuing review of approved proposals	<input type="checkbox"/>	v. Minor deviations from originally approved research causing no risk or minimal risk	<input type="checkbox"/>	vi. Progress/annual reports where there is no additional risk, for example activity limited to data analysis. Expedited review of SAEs/unexpected AEs will be conducted by SAE subcommittee.	<input type="checkbox"/>	vii. For multicentre research where a designated EC has approved the proposal, a participating EC may review participating centre specific information and modification in the study proposal through full committee meeting/ expedited review depending on the importance of local consent related issues involved specific to the centre.	<input type="checkbox"/>	viii. Research during emergencies and disasters (See Section 12 of ICMR Ethical Guidelines, 2017).	<input type="checkbox"/>	ix. Any other (please specify)	<input type="checkbox"/>
i. Involve non-identifiable specimen and human tissue from sources like blood banks, tissue banks and left-over clinical samples	<input type="checkbox"/>																		
ii. Involve clinical documentation materials that are non-identifiable (data, documents, records).	<input type="checkbox"/>																		
iii. Modification or amendment to approved protocol (administrative changes/correction of typographical errors and change in researcher(s))	<input type="checkbox"/>																		
iv. Revised proposals previously approved through expedited review, full review or continuing review of approved proposals	<input type="checkbox"/>																		
v. Minor deviations from originally approved research causing no risk or minimal risk	<input type="checkbox"/>																		
vi. Progress/annual reports where there is no additional risk, for example activity limited to data analysis. Expedited review of SAEs/unexpected AEs will be conducted by SAE subcommittee.	<input type="checkbox"/>																		
vii. For multicentre research where a designated EC has approved the proposal, a participating EC may review participating centre specific information and modification in the study proposal through full committee meeting/ expedited review depending on the importance of local consent related issues involved specific to the centre.	<input type="checkbox"/>																		
viii. Research during emergencies and disasters (See Section 12 of ICMR Ethical Guidelines, 2017).	<input type="checkbox"/>																		
ix. Any other (please specify)	<input type="checkbox"/>																		
<p>2. Is waiver of consent being requested ? Yes <input type="checkbox"/> No <input type="checkbox"/></p>																			
<p>3. Does the research involve vulnerable person²? Yes <input type="checkbox"/> No <input type="checkbox"/></p> <p>If Yes give details (attach a separate sheet):</p>																			

Signature of PI:

Comments of Project Cell:

Signature of Convener:

¹Refer to National Ethical Guidelines for Biomedical & Health Research Involving Human Participants 2017, Page 51 Table 4.2

²For details, refer to application for initial review, Section-C, 5(b)

³In case this is first submission, leave it blank

Annexure 4: Exemption from Review

INTERNATIONAL INSTITUTE FOR POPULATION SCIENCES



Deemed-to-Be-University
B. S. Devashi Marg (Govandi Station Road)
Deonar, Mumbai, Maharashtra 400088,
<https://www.iipsindia.ac.in/>

IIPS-IRB Exemption from Review Form

Title of study:

Principal Investigator (Name, Designation, and Affiliation):

4. Choose reasons why exemption from ethics review is requested^{1,2?}

x. Research on data in the public domain/ systematic reviews or meta-analyses	<input type="checkbox"/>
xi. Observation of public behavior/ information recorded without linked identifiers and disclosure would not harm the interests of the observed person	<input type="checkbox"/>
xii. Quality control and quality assurance audits in the institution)	<input type="checkbox"/>
xiii. Comparison among instructional techniques, curricula, or classroom management methods	<input type="checkbox"/>
xiv. Consumer acceptance studies related to taste and food quality	<input type="checkbox"/>
xv. Public health programmes by government agencies	<input type="checkbox"/>
xvi. Any other (please specify in 100 words)	<input type="checkbox"/>

Signature of PI:

Comments of Project Cell:

Signature of Convener:

¹ Select the category that applies best to your study and justify why you feel it should be exempted from review. For a detailed understanding of the type of studies that are exempt from review, refer to National Ethical Guidelines for Biomedical & Health Research Involving Human Participants 2017, Page 51 Table 4.2. ² Such as programme evaluation where the sole purpose of the exercise is refinement and improvement of the programme or monitoring (where there are no individual identifiers)

**In case this is first submission, leave it blank*

Annexure 5: Informed Assent form and guidelines

General Guidelines

[Title of your Institute]

Informed Assent Form (Respondents under age 18)

[Informed assent form should be on the Institute's letterhead]

Assent refers to agreeing or approving after thoughtful consideration an idea or suggestion to participate in research by a young person below the age of 18 years, who is old enough to understand the implications of any proposed research but not legally eligible to give consent. The assent has to be corroborated with the informed consent of the parent.

Obtaining Informed Assent from Children or Minors Parents, legal guardians, or a legally authorized official must sign consent forms permitting children or minors to participate in research projects. In addition, children and minors are required to sign an Assent Form.

The content of an assent form for children participating in research should be tailored to their age and understanding. It should be written in simple, clear language that aligns with their cognitive, social, and emotional development. Here's a breakdown of key points to include:

Key components to include are:

1. Explanation of the Study (Benefit & Purpose):

- a. briefly explain the research project and how it might benefit children like them In a child-friendly way. Mention the activities involved in the study, including any potential discomfort the child might experience.

2. Study Procedures and Potential Discomfort:

- a. Describe the activities involved in the study, using simple language and avoiding medical jargon.
- b. Mention any potential discomfort the child might experience and assure them it will be minimized.

3. Right to Ask Questions and Contact Information:

- a. Emphasize that the child can ask questions about the research at any time.
- b. Provide contact information for a person the child can reach with questions or concerns (e.g., researcher, parent liaison).

4. Voluntary Participation and Confidentiality:

- a. Clearly state that the child's participation is voluntary and they can refuse to participate or withdraw at any point without impacting their treatment or care..
- b. Assure them that refusing will not affect their treatment or care at the center.

5. Consent and Contact Information:

- a. Provide contact information for a person the child can reach with questions or concerns.

Sample:

[Project Title:]

My name is [Your Name], and I'm here to talk to you about a study we're doing about [Project Title and Brief description of the study in child-friendly language].

Your parent(s)/guardian(s) have already given their permission for you to participate, but it's completely up to you if you want to be part of it [explain the voluntary nature of participation and right not to participate and withdraw]

You may feel some inconvenience because of the time and effort to be a participant. You may also find some questions that we ask to be upsetting or may feel embarrassed to answer them [mention any potential discomfort in a gentle way].

You do not have to respond to any question that makes you uncomfortable and you may stop the interview at any time and nothing will happen. There are no direct benefits to participating in the study,

although you will help us understand what children like you want or need.

Your participation is entirely voluntary and you can stop the interview at any point of time even after having agreed to participate. If you decide not to participate it will not affect any benefits to which you are entitled. I want to assure you that the information you provide during the study will be kept private and confidential.

If you have any question, please feel free to ask them to me. Or you can also contact the Project PI on the following address. *[Address questions of the child regarding the survey if any]*

Principal Investigator: [Name, Affiliation, Office, Mobile, Email Address]

[Principal Investigator and Contact Information]

Do you agree to participate in this survey? *[Verification of child's consent]*

Tick the answer:

1. *Consent given along with signature/ thumb impression*
2. *Consent given but without signature/thumb impression*
3. *Consent Refused*

[Interviewer's Declaration]

I confirm that the individual has given consent freely. *I have taken consent from parents (assent from in case of minor) before the interview*

Interviewer's Name and signature: _____ *Date:* ____ / ____ / ____

Annexure 6 : Informed Consent form and guidelines


Guidelines for the Informed Consent

An informed consent form must include the following:

1. Obtaining an Informed Consent is not simply obtaining a signature on a prescribed format rather, it is a process of sharing information and addressing questions and concerns of the participant.
2. It is based on the principle that competent individuals are entitled to choose freely whether or not to participate or continue to participate in the research.
3. Participants must then give their consent to participate on an informed consent form developed specifically for the research project.
4. There are very few research situations where a participant's signature on informed consent is not required. However, permission from IRB is always required for waving off of the signature.
5. The informed consent form should be submitted in English as well as in local language(s).
6. The goal and objective of research in simple jargon-free language. The language should not only be scientifically accurate and simple, but should also be sensitive to the social and cultural context of the participant.
7. Informed consent is a continuous process involving three main components – a) providing relevant information to potential participants, b) ensuring the competence of the individual, ensuring the information is easily comprehended by the participants and c) ensuring voluntariness.

Annexure 6: Informed Consent form and guidelines

Part - A

INTERNATIONAL INSTITUTE FOR POPULATION SCIENCES	
 <p>Deemed-to-Be-University B. S. Devashi Marg (Govandi Station Road) Deonar, Mumbai, Maharashtra 400088, https://www.iipsindia.ac.in/</p>	IIPS-IRB Informed Consent Form

[Project Title:]

1. [Introduction]

*Greetings.... Self-introduction
Statement mentioning that it is research*

2. [Purpose of Your Study]

- Clear the research objectives and outcome of the study
- [Respondent's Role]-Explain the procedure to participate in the interview/survey. Explanation of all the research tools employed. Reasons or methods for inclusion/exclusion of the particular group or individual(s) in the community or in any other settings, for participation in the survey should be briefed.
- Detailed description of the methodology
- [Time]- Approx. estimated time to complete the survey
 - *The interview will take approximately -----mins to complete.*

3. [Risks or Benefits]-

- Risks: [Describe any potential risks/discomfort/inconvenience associated with participation.]
 - *You may feel some inconvenience because of the time and effort to be a participant. In case of sensitive surveys, including questions on You may also find some questions that we ask to be upsetting or may feel embarrassed to answer them. You do not have to respond to any question that makes you uncomfortable and you may stop the interview at any time and nothing will happen.*
- Benefits: [Explain any potential benefits to participants or community.]
 - *There are no direct benefits to participating in the study, although you will help us understand what children like you want or need*

4. [Privacy/Confidentiality/Data Security]

- It is necessary to maintain the privacy and confidentiality of participants at all stages.
- The extent of privacy, anonymity, and confidentiality that will be provided to participants
 - *The information shared by you will be kept confidential and will not be shared with anyone, and will be used only for research purposes.*
 -
- [Data Sharing- Data collected will be completely anonymized/partially anonymized]
 - *The data will only be used for research and planning purposes without any personal identification.*

Suppose in the case of Indirect Identifiers, you may give:

- *All the information you provide will be strictly confidential, and your name will not appear on the questionnaire. Instead, your questionnaire will contain an identification number that is known only by the principal investigator of this study.*
- *No one including your family members, friends, or other members of the community will ever know that you have not participated in the survey and no one will know what answers you gave since we do not collect information about your name etc.*
- [Information on any follow-ups of survey if any]
 - *The survey team may also re-contact you if it is necessary to complete the information in the survey.*
- [Voluntary nature of participation and Right not to participate and withdraw]
 - *Your participation is voluntary. You may refuse to participate or may discontinue your participation at any time during the survey. You can also choose not to answer any questions.*
- [Importance of the response/survey and future use of the information]
 - *Your responses are very important to us and the community, as these answers will represent many other people. This is an important study and I hope you will participate fully.*

5. [Contact information]

We will leave the necessary contact information with you. If you have any questions or concerns about this study, please contact on the address given below.

6. [Address questions of the Respondent regarding the survey if any]

- Do you have any questions?
 - *Should you have any question about the survey please feel free to ask me or contact the concerned authority.*

[Principal Investigator and Contact Information]

Principal Investigator: [Name, Affiliation, Office, Mobile, Email Address]

7. [Consent] Respondent's willingness to participate in the study

- *Do you agree to participate in this survey?*

[Verification of consent]

Tick the answer:

- 1. Consent is given along with signature/ thumb impression*
- 2. Consent is given but without signature/thumb impression*
- 3. Consent Refused*


[Interviewer's Declaration]

I have informed the respondent about the project, risk and benefit and also confidentially risk taken consent from the respondent before the interview.

Interviewer's Name: _____ *Date:* ____ / ____ / ____

Annexure 6: Informed Consent form and guidelines

Part - B

INTERNATIONAL INSTITUTE FOR POPULATION SCIENCES	
 <p>Deemed-to-Be-University B. S. Devashi Marg (Govandi Station Road) Deonar, Mumbai, Maharashtra 400088, https://www.iipsindia.ac.in/</p>	IIPS-IRB Informed Consent Form

Informed Consent Form

I, _____, have read the Participant Information Sheet for the above-mentioned project. The information provided in the sheet regarding the nature, purpose, safety, potential risks/benefits, and the expected duration of the study, as well as other relevant details, including my role as a study participant, has been explained to me in a language that I understand.

I confirm that:

- I have had the opportunity to ask questions, and all my queries have been answered to my satisfaction.
- I understand that my participation in this research study is entirely voluntary, and I have the right to withdraw from the study at any point without giving any reason and without affecting my current or future medical treatment or relationship with the researchers.
- I understand the risk & benefits of participating in this study.
- I understand that refusing to participate or withdrawing will not result in any penalty or loss of benefits to which I am entitled.
- I understand that my personal information and data collected during this study will be kept confidential. Only the researchers involved in the study, the sponsoring agencies, regulatory authorities, and IRB may access my records if necessary, for monitoring and auditing the study in line with the ethical guidelines.
- I understand that the data will be anonymized for any future use, and my identity will not be revealed in any reports or publications that come out of this research.

By signing this consent form, I willingly agree to participate in this study. I understand that I can withdraw at any time without giving a reason and without any loss of benefit.

For participants with limited or non-readers:

I, [Witness Name], have witnessed the consent procedure of the study participant. The participant had the opportunity to ask questions, and I confirm that the individual has given consent freely and voluntarily after understanding the study's purpose and their role in it.

Name of the Participant/Guardian: _____

Signature/Thumb Impression of the Participant/Guardian: _____

Witness (for non-readers): _____
(Signature and Name)

Name of the Person Administering the Consent: _____

Signature of the Person Administering the Consent: _____

Date: _____

Principal Investigator (PI): _____

Contact Information: [Insert PI's Contact Details]

Co-Principal Investigator (Co-PI): _____

Contact Information: [Insert Co-PI's Contact Details]

Note: All parties signing the consent form must date their own signature

Part A

INTERNATIONAL INSTITUTE FOR POPULATION SCIENCES



Deemed-to-Be-University
B. S. Devashi Marg (Govandi Station Road)
Deonar, Mumbai, Maharashtra 400088,
<https://www.iipsindia.ac.in/>

IIPS-IRB Self Declaration Form

DECLARATION BY THE PRINCIPAL INVESTIGATOR

Study Title: _____

I hereby declare that:

1. Voluntary written consent of the human subject will be obtained.
2. In case of children and mentally handicapped subjects-voluntary written informed consent of the parents/guardians will be obtained.
3. The probable risk involved in the project will be explained in full details to the subjects/parents/guardians.
4. Subjects/parents/guardians will be at liberty to opt out of the project at any time.
5. I will terminate the study at any stage, if I have probable cause to believe, in the exercise of the good faith, skill and careful judgement required for me that continuation of the experiment is likely to result in injury, disability of death to the experimental subject.

Date: _____

(Signature of Principal Investigator)
Deptt. _____

Part B

INTERNATIONAL INSTITUTE FOR POPULATION SCIENCES



Deemed-to-Be-University
B. S. Devashi Marg (Govandi Station Road)
Deonar, Mumbai, Maharashtra 400088,
<https://www.iipsindia.ac.in/>

IIPS-IRB Self Declaration Form

(DECLARATION BY THE PRINCIPAL INVESTIGATOR/DIRECTOR)

Study Title: _____

1. Is The Department/University ready to undertake the responsibility of the human subjects in case of injury? If yes, then will it include Yes/No/NA
 - Transportation charges Yes/No/NA
 - Hospitalization charges Yes/No/NA
2. Do you think that the study is so designed that they would yield meaningful results that could not be obtained by the other method? Yes/No/NA
3. Do you think that the animal experiments carried put support the need for clinical experimentation? Yes/No/NA
4. Do you think that the study would be conducted in a manner to avoid all unnecessary physical and mental suffering and injury? Yes/No/NA
5. Do you think the experiments have been planned in a manner so that the degree of risk to be taken would never exceed that determined by the humanitarian importance of the problem to be solved by the experiment? Yes/No/NA
6. Do you think that proper preparations would be made and adequate facilities provided to protect the study subject against even remote possibilities of injury, Disability or death; Yes/No/NA
7. Do you think that safeguards have been taken to see that the research would be conducted only by scientifically qualified persons who possess the requisite competence, experience and qualities to carry out the research? Yes/No/NA

Date:

(Signature of Principal Investigator)

(Signature of Director)

Sr. No.: /

अन्तर्राष्ट्रीय जनसंख्या विज्ञान संस्थान

(विश्वविद्यालय समतुल्य)*

स्वास्थ्य एवं परिवार कल्याण मंत्रालय, भारत सरकार का स्वायत्त संगठन
गोवंडी स्टेशन रोड, देवनार, मुम्बई- 400 088. भारत

(स्थापना/ Established in 1956)
बेहतर भविष्य के लिए क्षमता निर्माण
Capacity Building for a Better Future

International Institute for Population Sciences

(Deemed University)*

An Autonomous Organization of Ministry of Health & Family Welfare, Govt. of India
Govandi Station Road, Deonar, Mumbai -400 088. INDIA

No. /IIPS/PSC-54/IRB/

Date:

Institutional Review Board (IRB00013212)

ChairpersonProf. D.P Singh
TISS**Member Secretary**Ms Manjiri M Rane
IIPS**Convener**Prof. Aparajita
Chattopadhyay
IIPS**Members**Prof. Gajanan Velhal
KEM HospitalProf. Archana K. Roy
IIPSDr. Lalita Savardekar
NIRRHProf. Vaishali Kolhe
TISSMs. Sushmita Das
Society for Nutrition,
Education
& Health Action
(SNEHA)Dr. Vinod B Joshi
Advocate for Govt of
India - Law

Project title:	
Name & Address of Institution:	
Principal Investigator Name: Contact Number: E-mail ID:	Name of Co- PI/s:
Collaborators' Name, Address, Contact. No. & Email:	Sponsor:
Review Status: New Review/ Revised Review	
The following item [✓] have been received and reviewed in connection with the above study to be conducted by the above investigator.	
[] Participant Information Sheet Synopsis	[] Study Protocol /
[] Summary of Change Document (in case of a revision)	[] Informed Consent Form
[] Informed Assent Form (in case minors are involved)	[] Investigators' CVs
And have been [✓]	
[] Approved	
[] Conditionally approved (identify item and specify modification below or in accompanying letter)	
[] Rejected (identify item and specify reasons below or in accompanying letter)	
Comments (if any):	
Date of Approval:	
Please note:	
- Inform IRB immediately in case of any adverse events and serious adverse events.	

<ul style="list-style-type: none"> - Inform IRB in case of any change of study procedure, site and investigator. - Members of IRB have right to monitor the pretesting procedure with prior intimation. - Members of IRB have right to monitor the field procedure with prior intimation. 	
Convener IRB Committee	Chairperson IRB Committee